Clinical efficacy of Mannatide combined with Mesalazine in the treatment of ulcerative colitis
WANG Limei1 XIANG Yi2 WU Ying1 LIANG Cong1 BAI Junfang1
1.Department of Gastroenterology, Shaanxi Second Provincial People′s Hospital, Shaanxi Province, Xi′an 710005, China;
2.Department of Gastroenterology, the Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Shaanxi Province, Xianyang 710065, China
Abstract:Objective To explore the clinical efficacy of Mannatide combined with Mesalazine in the treatment of patients with ulcerative colitis. Methods A total of 106 patients with ulcerative colitis admitted to Shaanxi Second Provincial People′s Hospital and the Second Affiliated Hospital of Shaanxi University of Chinese Medicine from August 2014 to December 2017 were collected as observation objects, they were divided into observation group and control group according to the random number table method, with 53 cases in each group. The control group was given Mesalazine alone, while the observation group was given Mannatide combined with Mesalazine. The clinical effect and adverse reactions of the two groups were recorded. The peripheral blood immune indexes CD3+, CD4+, CD4+/CD8+, NK cells were detected by flow cytometry. The serum levels of matrix metalloproteinase (MMP) -1, MMP-2, MMP-9 were determined by enzyme-linked immunosorbent assay (ELISA). Results The total effective rate of the observation group was higher than that of the control group, the difference was statistically significant (P < 0.05). The CD3+, CD4+, CD4+/CD8+, NK cells levels in two groups after treatment were significantly higher than those before treatment, which in the observation group were higher than those in control group, the differences were statistically significant (P < 0.05). The MMP-1, MMP-2, MMP-9 levels in two groups after treatment were significantly lower than those before treatment, which in the observation group were lower than those in the control group, the differences were statistically significant (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion Mannatide combined with Mesalazine in the treatment of ulcerative colitis can improve clinical efficacy, immune functions and body repair ability, and it doesn′t increase the incidence of adverse reactions, it′s safe and reliable.